Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer

International Journal of Molecular Medicine

Volumn 33, Issue 6, 2014, Pages 1514-1522

  Wang, Yiru ^a   Yao, Binwei ^b   Wang, Y U ^a,c   Zhang, Mingbo ^a   Fu, Shuai ^a   Gao, Hanjing ^a   Peng, Ruiyun ^b   Zhang, Lingqiang ^b   Tang, Jie ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Forkhead box M1; Metformin; Migration; Prostate cancer

Indexed keywords

FORKHEAD BOX M1 TRANSCRIPTION FACTOR; METFORMIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL LINE; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; WOUND HEALING;

CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; MALE; METFORMIN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; WOUND HEALING;

EID: 84899499476     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1707     Document Type: Article

References (41)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Christiansen JJ: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326, 2006.
3. Laoukili J, Kooistra MRH, Brás A, et al: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136, 2005. (Pubitemid 40268127)
4. Yang DK, Son CH, Lee SK, Choi PJ, Lee KE and Roh MS: Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol 40: 464-470, 2009.
5. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM and Kemmner W: Identification of early molecular markers for breast cancer. Mol Cancer 10: 15, 2011.
6. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300, 2007. (Pubitemid 47395167)
7. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Lyubimov A and Costa RH: Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66: 1712-1720, 2006. (Pubitemid 43259956)
8. Sun HC, Li M, Lu JL, et al: Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep 25: 1533-1539, 2011.
9. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
10. Green MR, Aya-Bonilla C, Gandhi MK, et al : Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 50: 313-326, 2011.
11. Huynh KM, Soh JW, Dash R, Sarkar D, Fisher PB and Kang D: FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J Cell Physiol 226: 194-204, 2011.
12. Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK and Al-Kuraya KS: Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 178: 537-547, 2011.
13. Bektas N1, Haaf At, Veeck J, et al: Tight correlation between expression of the Forkhead transcription factor FOXMl and HER2 in human breast cancer. BMC Cancer 8: 42, 2008.
14. Xia L1, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y and Wu K: The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 33: 2250-2259, 2012.
15. Wang Y1, Wen L, Zhao SH, Ai ZH, Guo JZ and Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 79: 173-179, 2013.
16. Wang IC, Chen YJ, Hughes D, et al: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894, 2005. (Pubitemid 41747132)
17. Ahmad A, Wang Z, Kong D, et al: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 122: 337-346, 2010.
18. Priller M, Pöschl J, Abrão L, et al: Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17: 6791-6801, 2011.
19. Li Q, Zhang N, Jia Z, et al: Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 69: 3501-3509, 2009.
20. Karadedou CT, Gomes AR, Chen J, et al: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 31: 1845-1858, 2012.
21. Dai B, Kang SH, Gong W, et al: Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26: 6212-6219, 2007. (Pubitemid 47414378)
22. Balli D, Ustiyan V, Zhang Y, et al: Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J 32: 231-244, 2013.
23. Yang C, Chen H, Tan G, et al: FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Lett 340: 104-112, 2013.
24. Del Barco S, Vazquez-Martin A, Cufi S, et al: Metformin: multi-faceted protection against cancer. Oncotarget 2: 896-917, 2011.
25. Hadad SM, Hardie DG, Appleyard V and Thompson AM: Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol: Dec 12, 2013 (Epub ahead of print).
26. He SY, Shen HW, Xu L, et al: FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol 127: 601-610, 2012.
27. Lu K, Yin X, Weng T, et al: Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1. Nat Cell Biol 10: 994-1002, 2008.
28. Yung MM CD, Liu VW, Yao KM and Ngan HY: Activation of AMPK inhibits cervical cancer cell growth through AKT FOXO3a FOXM1 signaling cascade. BMC Cancer 13: 327 2013.
29. Hugo H, Ackland ML, Blick T, et al: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007. (Pubitemid 47509716)
30. Korver W, Roose J, Heinen K, et al: The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. Genomics 46: 435-442, 1997. (Pubitemid 28063292)
31. Laoukili J, Stahl M and Medema RH: FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102, 2007. (Pubitemid 44881197)
32. Nieto MA: Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol 53: 1541-1547, 2009.
33. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
34. Slabáková E, Pernicová Z, Slavíè ková E, Staršíchová A, Kozubík A and Souèek K: TGF- â1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. Prostate 71: 1332-1343, 2011.
35. Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84, 2013.
36. Saitoh M and Miyazawa K: Transcriptional and post-transcriptional regulation in TGF-β-mediated epithelial-mesenchymal transition. J Biochem 151: 563-571, 2012.
37. Lin T, Ponn A, Hu X, Law BK and Lu J: Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 29: 4896-4904, 2010.
38. Gorbachinsky I, Akpinar H and Assimos DG: Metabolic syndrome and urologic diseases. Rev Urol 12: e157-e180, 2010.
39. Parsons JK, Carter HB, Partin AW, et al: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91: 2562-2568, 2006. (Pubitemid 44024618)
40. Jalving M, Gietema JA, Lefrandt JD, et al: Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380, 2010.
41. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA: Metformin against TGF-β-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9: 4461-4468, 2010.